RxDoctor Payments Data

Richard Galperin

Foot Surgery · Dallas, TXNPI 1457311284

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Merck at 51.1% of the total. Reporting peaked in 2019 at $6,605 and has fallen 86.7% since, to $880 in 2025.

$11,509in general payments, 2019–2025

Across 179 payments — averaging $64.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$6K
  • Stryker$2K
  • Endo Pharmaceuticals Inc.$823
  • Organogenesis Inc.$555
  • Smith+Nephew$392
  • Kerecis Limited$332
  • plus $2K from 29 others
$101,483in research payments, 2019–2025

Across 30 payments — averaging $3382.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo Pharmaceuticals Inc.$54K
  • Integra Lifesciences Corporation$48K

What the payments were for

  • Speaking & faculty fees$4,09536%
  • Travel & lodging$2,73224%
  • Food & beverage$4,58640%
  • Gifts$951%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,509 in reported general payments places this provider in the 85th percentile of 71 foot surgery providers in Texas.

See all foot surgery providers in Texas

Medicare billing

Part B allowed, 2024
$64,832
Medicare patients
182
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole68$1,427
Gabapentin50$746
Ammonium Lactate23$475
Ibuprofen15$176
Cephalexin13$102
Meloxicam29$41

Paid to pharmacies, not to this prescriber.

Other foot surgery in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →